Drugs / LBL-024
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07281976 | Jan 2026 → Dec 2027 expected | triple-negative breast carcinoma | Nanjing Leads Biolabs Co.,Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07042802 | Dec 2025 → Dec 2027 expected | ovarian cancer | Nanjing Leads Biolabs Co.,Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07099430 | Sep 2025 → Oct 2027 expected | melanoma | Nanjing Leads Biolabs Co.,Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06157827 | Dec 2023 → Dec 2026 expected | neuroendocrine carcinoma | Nanjing Leads Biolabs Co.,Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05170958 | Jan 2022 → Dec 2026 expected | neoplasm | Nanjing Leads Biolabs Co.,Ltd | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07331155 | Feb 2026 → Dec 2028 expected | — | Nanjing Leads Biolabs Co.,Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT07111546 | Oct 2025 → Dec 2027 expected | — | Nanjing Leads Biolabs Co.,Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT06783647 | Jun 2025 → Dec 2026 expected | high grade malignant neoplasm | Nanjing Leads Biolabs Co.,Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LBL-024 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06783647 ↗ |
| Route | Intravenous | “LBL-024 Intravenous infusion.” NCT07042802 ↗ |